It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, ...

TransMedics' strong Q4 performance and market share growth signal a promising future for investors. Click here to find out ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

New York, New York-- (Newsfile Corp. - March 11, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

Over the twelve months to December 2024, TransMedics Group recorded an accrual ratio of 0.36. Unfortunately, that means its free cash flow was a lot less than its statutory profit, which makes us ...

TransMedics Group's organ care system can preserve multiple organs, but livers are responsible for 70% of total sales. OrganOx markets a normothermic machine perfusion device approved to preserve ...

SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about 62% from the peak it set last August. The company's warm perfusion ...